IP Library › Granted Patent US 12,339,290
Granted Patent B2
US 12,339,290 · App. 18/770,102 · Granted Jun 24, 2025

Phospho-tau antibodies and methods of use

Inventors: Andreas Jeromin (Alachua, FL); Krish Venkat (Lawrenceville, NJ)
Assignee: ALZPATH, INC.
G01N33/6896C07K16/18G01N33/53G01N33/6857C07K2317/20C07K2317/24C07K2317/52C07K2317/565G01N2333/4704G01N2333/4709G01N2333/96416G01N2800/2821
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,339,290
App. No.
18/770,102
Granted
Jun 24, 2025
Kind
B2
Abstract

Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.

Claims (97)

1. An anti-tau antibody or antigen binding fragment thereof comprising:

a heavy chain comprising a variable heavy chain (VH) domain; and

a light chain comprising a variable light chain (VL) domain, wherein:

the VH domain comprises HCDR1 sequence comprising SEQ ID NO: 2, HCDR2 sequence comprising SEQ ID NO: 7, and HCDR3 sequence comprising SEQ ID NO: 11; and

the VL domain comprises LCDR1 sequence comprising SEQ ID NO: 15, LCDR2 sequence comprising SEQ ID NO: 21, and LCDR3 sequence comprising SEQ ID NO: 25.

2. An anti-tau antibody or antigen binding fragment thereof comprising:

a heavy chain comprising a variable heavy chain (VH) domain; and

a light chain comprising a variable light chain (VL) domain, wherein:

the VH domain comprises HCDR1 sequence comprising SEQ ID NO: 4, HCDR2 sequence comprising SEQ ID NO: 7, and HCDR3 sequence comprising SEQ ID NO: 12; and

the VL domain comprises LCDR1 sequence comprising SEQ ID NO:

18, LCDR2 sequence comprising SEQ ID NO: 23, and LCDR3 sequence comprising SEQ ID NO: 28.

3. An anti-tau antibody or antigen binding fragment thereof comprising:

a heavy chain comprising a variable heavy chain (VH) domain; and

a light chain comprising a variable light chain (VL) domain, wherein:

the VH domain comprises HCDR1 sequence comprising SEQ ID NO: 5, HCDR2 sequence comprising SEQ ID NO: 9, and HCDR3 sequence comprising SEQ ID NO: 13; and

the VL domain comprises LCDR1 sequence comprising SEQ ID NO: 19, LCDR2 sequence comprising SEQ ID NO: 21, and LCDR3 sequence comprising SEQ ID NO: 29.

4. An anti-tau antibody or antigen binding fragment thereof comprising:

a heavy chain comprising a variable heavy chain (VH) domain; and

a light chain comprising a variable light chain (VL) domain, wherein:

the VH domain comprises HCDR1 sequence comprising SEQ ID NO: 1, HCDR2 sequence comprising SEQ ID NO: 6, and HCDR3 sequence comprising SEQ ID NO: 10; and

the VL domain comprises LCDR1 sequence comprising SEQ ID NO: 14, LCDR2 sequence comprising SEQ ID NO: 20, and LCDR3 sequence comprising SEQ ID NO: 24.

5. An anti-tau antibody or antigen binding fragment thereof comprising:

a heavy chain comprising a variable heavy chain (VH) domain; and

a light chain comprising a variable light chain (VL) domain, wherein:

the VH domain comprises HCDR1 sequence comprising SEQ ID NO: 2, HCDR2 sequence comprising SEQ ID NO: 7, and HCDR3 sequence comprising SEQ ID NO: 11; and

the VL domain comprises LCDR1 sequence comprising SEQ ID NO: 16, LCDR2 sequence comprising SEQ ID NO: 22, and LCDR3 sequence comprising SEQ ID NO: 26.

6. An anti-tau antibody or antigen binding fragment thereof comprising:

a heavy chain comprising a variable heavy chain (VH) domain; and

a light chain comprising a variable light chain (VL) domain, wherein:

the VH domain comprises HCDR1 sequence comprising SEQ ID NO: 3, HCDR2 sequence comprising SEQ ID NO: 8, and HCDR3 sequence comprising SEQ ID NO: 10; and

the VL domain comprises LCDR1 sequence comprising SEQ ID NO: 17, LCDR2 sequence comprising SEQ ID NO: 20, and LCDR3 sequence comprising SEQ ID NO: 27.

7. The anti-tau antibody or antigen binding fragment thereof of claim 1 , wherein the VH domain comprises SEQ ID NO: 31, and the VL domain comprises SEQ ID NO: 36.

8. The anti-tau antibody or antigen binding fragment thereof of claim 2 , wherein the VH domain comprises SEQ ID NO: 33, and the VL domain comprises SEQ ID NO: 39.

9. The anti-tau antibody or antigen binding fragment thereof of claim 3 , wherein the VH domain comprises SEQ ID NO: 34, and the VL domain comprises SEQ ID NO: 40.

10. The anti-tau antibody or antigen binding fragment thereof of claim 4 , wherein the VH domain comprises SEQ ID NO: 30, and the VL domain comprises SEQ ID NO: 35.

11. The anti-tau antibody or antigen binding fragment thereof of claim 5 , wherein the VH domain comprises SEQ ID NO: 31, and the VL domain comprises SEQ ID NO: 37.

12. The anti-tau antibody or antigen binding fragment thereof of claim 6 , wherein the VH domain comprises SEQ ID NO: 32, and wherein the VL domain comprises SEQ ID NO: 38.

13. The anti-tau antibody or antigen binding fragment thereof of claim 1 , wherein the heavy chain comprises SEQ ID NO: 43, and the light chain comprises SEQ ID NO: 44.

14. The anti-tau antibody or antigen binding fragment thereof of claim 2 , wherein the heavy chain comprises SEQ ID NO: 48, and the light chain comprises SEQ ID NO: 49.

15. The anti-tau antibody or antigen binding fragment thereof of claim 3 , wherein the heavy chain comprises SEQ ID NO: 50, and the light chain comprises SEQ ID NO: 51.

16. The anti-tau antibody or antigen binding fragment thereof of claim 4 , wherein the heavy chain comprises SEQ ID NO: 41, and the light chain comprises SEQ ID NO: 42.

17. The anti-tau antibody or antigen binding fragment thereof of claim 5 , wherein the heavy chain comprises SEQ ID NO: 43, and the light chain comprises SEQ ID NO: 45.

18. The anti-tau antibody or antigen binding fragment thereof of claim 6 , wherein the heavy chain comprises SEQ ID NO: 46, and the light chain comprises SEQ ID NO: 47.

19. The anti-tau antibody or antigen binding fragment thereof of claim 1 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a tau protein.

20. The anti-tau antibody or antigen binding fragment thereof of claim 1 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a human tau protein.

21. The anti-tau antibody or antigen binding fragment thereof of claim 1 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a phosphorylated tau protein.

22. The anti-tau antibody or antigen binding fragment thereof of claim 21 , wherein the phosphorylated tau protein is selected from the group consisting of pTau-181, pTau-212, pTau-217, pTau-231, pTau-214, and pTau-220.

23. The anti-tau antibody or antigen binding fragment thereof of claim 22 , wherein the phosphorylated tau protein is pTau-181, pTau-217, or pTau-231.

24. The anti-tau antibody or antigen binding fragment thereof of claim 1 , wherein the anti-tau antibody is a monoclonal antibody.

25. The anti-tau antibody or antigen binding fragment thereof of claim 1 , wherein the anti-tau antibody is a rabbit monoclonal antibody.

26. The anti-tau antibody or antigen binding fragment thereof of claim 1 , wherein the anti-tau antibody is a chimeric antibody or antigen binding fragment thereof.

27. The anti-tau antibody or antigen binding fragment thereof of claim 1 , wherein the anti-tau antibody comprises an IgG1 constant region.

28. The anti-tau antibody or antigen binding fragment thereof of claim 2 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a tau protein.

29. The anti-tau antibody or antigen binding fragment thereof of claim 2 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a human tau protein.

30. The anti-tau antibody or antigen binding fragment thereof of claim 2 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a phosphorylated tau protein.

31. The anti-tau antibody or antigen binding fragment thereof of claim 30 , wherein the phosphorylated tau protein is selected from the group consisting of pTau-181, pTau-212, pTau-217, pTau-231, pTau-214, and pTau-220.

32. The anti-tau antibody or antigen binding fragment thereof of claim 31 , wherein the phosphorylated tau protein is pTau-181, pTau-217, or pTau-231.

33. The anti-tau antibody or antigen binding fragment thereof of claim 2 , wherein the anti-tau antibody is a monoclonal antibody.

34. The anti-tau antibody or antigen binding fragment thereof of claim 2 , wherein the anti-tau antibody is a rabbit monoclonal antibody.

35. The anti-tau antibody or antigen binding fragment thereof of claim 2 , wherein the anti-tau antibody is a chimeric antibody or antigen binding fragment thereof.

36. The anti-tau antibody or antigen binding fragment thereof of claim 2 , wherein the anti-tau antibody comprises an IgG1 constant region.

37. The anti-tau antibody or antigen binding fragment thereof of claim 3 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a tau protein.

38. The anti-tau antibody or antigen binding fragment thereof of claim 3 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a human tau protein.

39. The anti-tau antibody or antigen binding fragment thereof of claim 3 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a phosphorylated tau protein.

40. The anti-tau antibody or antigen binding fragment thereof of claim 39 , wherein the phosphorylated tau protein is selected from the group consisting of pTau-181, pTau-212, pTau-217, pTau-231, pTau-214, and pTau-220.

41. The anti-tau antibody or antigen binding fragment thereof of claim 40 , wherein the phosphorylated tau protein is pTau-181, pTau-217, or pTau-231.

42. The anti-tau antibody or antigen binding fragment thereof of claim 3 , wherein the anti-tau antibody is a monoclonal antibody.

43. The anti-tau antibody or antigen binding fragment thereof of claim 3 , wherein the anti-tau antibody is a rabbit monoclonal antibody.

44. The anti-tau antibody or antigen binding fragment thereof of claim 3 , wherein the anti-tau antibody is a chimeric antibody or antigen binding fragment thereof.

45. The anti-tau antibody or antigen binding fragment thereof of claim 3 , wherein the anti-tau antibody comprises an IgG1 constant region.

46. The anti-tau antibody or antigen binding fragment thereof of claim 4 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a tau protein.

47. The anti-tau antibody or antigen binding fragment thereof of claim 5 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a human tau protein.

48. The anti-tau antibody or antigen binding fragment thereof of claim 4 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a phosphorylated tau protein.

49. The anti-tau antibody or antigen binding fragment thereof of claim 48 , wherein the phosphorylated tau protein is selected from the group consisting of pTau-181, pTau-212, pTau-217, pTau-231, pTau-214, and pTau-220.

50. The anti-tau antibody or antigen binding fragment thereof of claim 49 , wherein the phosphorylated tau protein is pTau-181, pTau-217, or pTau-231.

51. The anti-tau antibody or antigen binding fragment thereof of claim 4 , wherein the anti-tau antibody is a monoclonal antibody.

52. The anti-tau antibody or antigen binding fragment thereof of claim 4 , wherein the anti-tau antibody is a rabbit monoclonal antibody.

53. The anti-tau antibody or antigen binding fragment thereof of claim 4 , wherein the anti-tau antibody is a chimeric antibody or antigen binding fragment thereof.

54. The anti-tau antibody or antigen binding fragment thereof of claim 4 , wherein the anti-tau antibody comprises an IgG1 constant region.

55. The anti-tau antibody or antigen binding fragment thereof of claim 5 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a tau protein.

56. The anti-tau antibody or antigen binding fragment thereof of claim 5 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a human tau protein.

57. The anti-tau antibody or antigen binding fragment thereof of claim 6 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a phosphorylated tau protein.

58. The anti-tau antibody or antigen binding fragment thereof of claim 57 , wherein the phosphorylated tau protein is selected from the group consisting of pTau-181, pTau-212, pTau-217, pTau-231, pTau-214, and pTau-220.

59. The anti-tau antibody or antigen binding fragment thereof of claim 58 , wherein the phosphorylated tau protein is pTau-181, pTau-217, or pTau-231.

60. The anti-tau antibody or antigen binding fragment thereof of claim 5 , wherein the anti-tau antibody is a monoclonal antibody.

61. The anti-tau antibody or antigen binding fragment thereof of claim 5 , wherein the anti-tau antibody is a rabbit monoclonal antibody.

62. The anti-tau antibody or antigen binding fragment thereof of claim 5 , wherein the anti-tau antibody is a chimeric antibody or antigen binding fragment thereof.

63. The anti-tau antibody or antigen binding fragment thereof of claim 5 , wherein the anti-tau antibody comprises an IgG1 constant region.

64. The anti-tau antibody or antigen binding fragment thereof of claim 6 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a tau protein.

65. The anti-tau antibody or antigen binding fragment thereof of claim 6 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a human tau protein.

66. The anti-tau antibody or antigen binding fragment thereof of claim 6 , wherein the anti-tau antibody or antigen binding fragment thereof specifically binds to a phosphorylated tau protein.

67. The anti-tau antibody or antigen binding fragment thereof of claim 66 , wherein the phosphorylated tau protein is selected from the group consisting of pTau-181, pTau-212, pTau-217, pTau-231, pTau-214, and pTau-220.

68. The anti-tau antibody or antigen binding fragment thereof of claim 67 , wherein the phosphorylated tau protein is pTau-181, pTau-217, or pTau-231.

69. The anti-tau antibody or antigen binding fragment thereof of claim 6 , wherein the anti-tau antibody is a monoclonal antibody.

70. The anti-tau antibody or antigen binding fragment thereof of claim 6 , wherein the anti-tau antibody is a rabbit monoclonal antibody.

71. The anti-tau antibody or antigen binding fragment thereof of claim 6 , wherein the anti-tau antibody is a chimeric antibody or antigen binding fragment thereof.

72. The anti-tau antibody or antigen binding fragment thereof of claim 6 , wherein the anti-tau antibody comprises an IgG1 constant region.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2024
From: JEROMIN, ANDREAS; VENKAT, ANNA
To: ALZPATH, INC.
Reel/Frame 068486/0843 →
Continuity (4)
Continuation 18599751 · Mar 8, 2024
Continuation PCTUS2022042963 · Sep 8, 2022
Provisional Application 63242437 · Sep 9, 2021
Related Publication 20240360206A1 · Oct 31, 2024
References Cited (93)
US 4694778A · Learn et al. · 1987 [cited by applicant]
US 9371376B2 · Alderfer et al. · 2016 [cited by applicant]
US 9447179B2 · Winderickx et al. · 2016 [cited by applicant]
US 10393759B2 · Wilson et al. · 2019 [cited by applicant]
US 11275092B2 · Wilson et al. · 2022 [cited by applicant]
US 20040219509A1 · Valkirs et al. · 2004 [cited by applicant]
US 20050260697A1 · Wang et al. · 2005 [cited by applicant]
US 20050272110A1 · Drukier · 2005 [cited by applicant]
US 20090159812A1 · Livingston · 2009 [cited by applicant]
US 20110003707A1 · Goix et al. · 2011 [cited by applicant]
US 20140094386A1 · Wilson et al. · 2014 [cited by applicant]
US 20160376351A1 · Adolfsson · 2016 [cited by examiner]
US 20170082641A1 · Rhyne et al. · 2017 [cited by applicant]
US 20170106084A1 · Bader · 2017 [cited by examiner]
US 20170137502A1 · Pfeifer et al. · 2017 [cited by applicant]
US 20180080945A1 · Goetzl · 2018 [cited by examiner]
US 20180238910A1 · Kang et al. · 2018 [cited by applicant]
US 20180321261A1 · Stanley · 2018 [cited by applicant]
US 20190033328A1 · Tokuda et al. · 2019 [cited by applicant]
US 20190169275A1 · Griswold-Prenner et al. · 2019 [cited by applicant]
US 20200377609A1 · Sievers et al. · 2020 [cited by applicant]
US 20220018856A1 · Jannes et al. · 2022 [cited by applicant]
US 20220146535A1 · Chai et al. · 2022 [cited by applicant]
US 20220229074A1 · Wilson et al. · 2022 [cited by applicant]
US 20220244276A1 · Wilson et al. · 2022 [cited by applicant]
US 20240353428A1 · Jeromin et al. · 2024 [cited by applicant]
WO WO2010011506A2 · 2010 [cited by applicant]
WO WO2019085804A1 · 2019 [cited by applicant]
WO WO2019094595A2 · 2019 [cited by applicant]
WO WO2021178545A1 · 2021 [cited by applicant]
WO WO2022115705A2 · 2022 [cited by applicant]
WO WO2022150735A1 · 2022 [cited by applicant]
WO WO2023039107A2 · 2023 [cited by applicant]
WO WO2024192404A1 · 2024 [cited by applicant]
Kipriyanov et al., Mol Biotechnol. Jan. 2004;26(1):39-60. doi: 10.1385/MB:26:1:39. PMID: 14734823. [cited by examiner]
Wegmann et al., Curr Opin Neurobiol. Aug. 2021;69:131-138. doi: 10.1016/j.conb.2021.03.003. Epub Apr. 21, 2021. PMID: 33892381. [cited by examiner]
Janeway et al., Immunobiology, 3rd edition, Garland Publishing Inc., 1997, pp. 3:1-3:11. [cited by examiner]
Rudikoff et al., Proc Natl Acad Sci USA. Mar. 1982;79(6):1979-83. [cited by examiner]
Edwards et al., J Mol Biol. Nov. 14, 2003;334(1): 103-18. [cited by examiner]
Goel et al., J Immunol. Dec. 15, 2004; 173(12):7358-67. [cited by examiner]
Llyod et al., Protein Eng Des Sel. Mar. 2009;22(3):159-68. doi: 10.1093/protein/gzn058. Epub Oct. 29, 2008. [cited by examiner]
Lescar, et al. Journal of Biological Chemistry 270.30 (1995): 18067-18076. [cited by examiner]
Kanyavuz et al., Nat Rev Immunol. Jun. 2019;19(6):355-368. doi: 10.1038/S41577-019-0126-7. [cited by examiner]
Al-Lazikani, Bissan. et al. Standard Conformations for the Canonical Structures of Immunoglobulins. Journal of Molecular Biology 273(4):927-948 (1997). [cited by applicant]
Bird, Robert E. et al. Single-chain Antigen-binding Proteins. Science 242(4877):423-426 (1988). [cited by applicant]
Clackson, Tim. et al. Making Antibody Fragments using Phage Display Libraries. Nature 352(6336):624-628 (1991). [cited by applicant]
Colbere-Garapin, Florence et al. A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells. Journal of Molecular Biology 150(1):1-14 (1981). [cited by applicant]
Cole, S.P.C. et al. The EBV-Hybridoma Technique and its Application to Human Lung Cancer. Monoclonal Antibodies and Cancer Therapy 27:77-96 (1985). [cited by applicant]
Courtenay-Luck, N S., Chapter 8: Genetic Manipulation of Monoclonal Antibodies. Monoclonal Antibodies: Production, Engineering and Clinical Application pp. 166-179 (1995). [cited by applicant]
Crouse, Gray F. et al. Expression and Amplification of Engineered Mouse Dihydrofolate Reductase Minigenes. Molecular Cell Biology 3(2):257-266 (1983). [cited by applicant]
Cummings et al. Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement 8(1):e12295 (2022). [cited by applicant]
Goldspiel, Barry R. et al. Human Gene Therapy. Clinical Pharmacy 12(7):488-505 (1993). [cited by applicant]
Hampel, Harald et al. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol. Jan. 2010;45(1):30-40. doi: 10.1016/j.exger.2009.10.010. Epub Oct. 22, 2009. [cited by applicant]
Hanes, Jozef. et al. In Vitro Selection and Evolution of Functional Proteins by Using Ribosome Display. PNAS USA 94(10):4937-4942 (1997). [cited by applicant]
Honegger, Annemarie. et al. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. Journal of Molecular Biology 309(3):657-670 (2001). [cited by applicant]
Huse, William D. et al. Generation of a Large Combinatorial Library of The Immunoglobulin Repertoire In Phage Lambda. Science 246(4935):1275-1281 (1989). [cited by applicant]
Huston, James S. et al. Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in [cited by applicant]
Huston, James S. et al. Protein Engineering of Single-chain Fv Analogs and Fusion Proteins. Methods in Enzymology 203:46-96 (1991). [cited by applicant]
Jonaitis, Erin M. et al. Plasma phosphorylated tau 217 in preclinical Alzheimer's disease. Brain Commun. Mar. 6, 2023;5(2):fcad057. doi: 10.1093/braincomms/fcad057. eCollection 2023. [cited by applicant]
Kabat, Elvin A. et al. Sequences of Proteins of Immunological Interest, 5th Edition. U.S. Department of Health and Human Services NIH Publication No. 91-3242 (1991). [cited by applicant]
Köhler, G. et al. Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity. Nature 256(5517):495-497 (1975). [cited by applicant]
Kozbor, Danuta et al. The Production of Monoclonal Antibodies From Human Lymphocytes. Immunology Today 4(3):72-79 (1983). [cited by applicant]
Kutmeier, G. et al. Assembly of Humanized Antibody Genes from Synthetic Oligonucleotides Using a Single-round PCR. Biotechniques 17(2):242-246 (1994). [cited by applicant]
Larrick, James W, and Kirk E. Fry. PCR amplification of antibody genes. Methods 2(2):106-110 (1991). [cited by applicant]
Lefranc, Marie-Paule. et al. The IMGT Unique Numbering for Immunoglobulins. T-Cell Receptors and Ig-Like Domains. The Immunologist 7(4):132-136 (1999). [cited by applicant]
Lowy, Israel. et al. Isolation of Transforming DNA: Cloning the Hamster aprt Gene. Cell 22(3):817-823 (1980). [cited by applicant]
MacCallum, Robert M. et al. Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography. Journal of Molecular Biology 262(5):732-745 (1996). [cited by applicant]
Mielke et al. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurol 78(9):1108-1117 (2021). [cited by applicant]
Mintun, M. et al., Donanumab in Early Alzheimer's Disease, N Engl J Med, 2021, vol. 384, No. 18, pp. 1691-1704. [cited by applicant]
Morgan, Richard A, and W F Anderson. Human Gene Therapy. Annual Review of Biochemistry 62:191-217 (1993). [cited by applicant]
Morrison, Sherie L. et al. Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains With Human Constant Region Domains. PNAS USA 81(21):6851-6855 (1984). [cited by applicant]
Mulligan, R. C, and P. Berg. Selection for Animal Cells That Express the [cited by applicant]
Mulligan, Richard C. The Basic Science of Gene Therapy. Science 260(5110):926-932 (1993). [cited by applicant]
Neddens, Joerg et al. Phosphorylation of different tau sites during progression of Alzheimer's disease. Acta Neuropathol Commun. Jun. 29, 2018;6(1):52. doi: 10.1186/s40478-018-0557-6. [cited by applicant]
Neuberger, Michael S. et al. Recombinant Antibodies Possessing Novel Effector Functions. Nature 312(5995):604-608 (1984). [cited by applicant]
No Author, Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure, retrieved from internet on Apr. 2, 2024: https://www.businesswire.com/news/home/20240321224578… [cited by applicant]
O'Hare, K. et al. Transformation of Mouse Fibroblasts to Methotrexate Resistance by a Recombinant Plasmid Expressing a Prokaryotic Dihydrofolate Reductase. PNAS USA 78(3):1527-1531 (1981). [cited by applicant]
PCT/US2022/042963 International Search Report and Written Opinion dated Jun. 14, 2023. [cited by applicant]
PCT/US2024/020266 International Search Report and Written Opinion dated Jul. 8, 2024. [cited by applicant]
Pontecorvo, M. et al., Association of Donanemab Treatment with Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease, JAMA Neurology, 2022, vol. 79, No. 12, pp. 1250-1259. [cited by applicant]
Santerre, Robert F. et al. Expression of Prokaryotic Genes for Hygromycin B and G418 Resistance as Dominant-selection Markers in Mouse L Cells. Gene 30(1-3):147-156 (1984). [cited by applicant]
Skerra, Arne. et al. Assembly of a Functional Immunoglobulin Fv Fragment in [cited by applicant]
Szybalska, Elizabeth Hunter et al. Genetics of Human Cell Lines, IV. DNA-mediated Heritable Transformation of a Biochemical Trait. PNAS USA 48(12):2026-2034 (1962). [cited by applicant]
Takeda, Shun-Ichi. et al. Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences. Nature 314(6010):452-454 (1985). [cited by applicant]
Tolstoshev, Paul. Gene Therapy, Concepts, Current Trials and Future Directions. Annual Review Pharmacology and Toxicology 32:573-596 (1993). [cited by applicant]
U.S. Appl. No. 18/599,751 Notice of Allowance dated Feb. 12, 2025. [cited by applicant]
U.S. Appl. No. 18/599,751 Office Action dated Oct. 17, 2024. [cited by applicant]
Ward, E Sally. et al. Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from [cited by applicant]
Ward, et al., Genetic Manipulation and Expression of Antibodies. Monoclonal Antibodies: Principles and Applications, Wiley-Liss Inc (pp. 137-185) (1995). [cited by applicant]
Whitelegg, Nicholas R, and Reed, Anthony R. WAM: An Improved Algorithm for Modelling Antibodies on the WEB. Protein Engineering 13(12):819-824 (2000). [cited by applicant]
Wigler, M. et al. Transformation of Mammalian Cells With an Amplifiable Dominant-acting Gene. PNAS USA 77(6):3567-3570 (1980). [cited by applicant]
Wigler, Michael. et al. Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells. Cell 11(1):223-232 (1977). [cited by applicant]
Wu, George Y. et al. Delivery systems for Gene Therapy. Biotherapy 3(1):87-95 (1991). [cited by applicant]